Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy

Kidney International

Volumn 64, Issue 3, 2003, Pages 817-828

  Jenkins, Alicia J ^b   Lyons, Timothy J ^b   Zheng, Deyi ^b   Otvos, James D ^b   Lackland, Daniel T ^b   McGee, Daniel ^b   Garvey, W Timothy ^b   Klein, Richard L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

Diabetes mellitus; Lipoproteins; Nephropathy; NMR

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROGENESIS; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DYSLIPOPROTEINEMIA; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0041931066     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00164.x     Document Type: Article

References (47)

1. Diabetes: 1996 Vital Statistics. Alexandria, VA, American Diabetes Association, 1996.
2. HERMAN WH, CROFFORD OB: Diabetic control and complications, chapter 41, in Chronic Complication of Diabetes (vol 1), edited by PICKUP JC, WILLIAMS G, 2nd edition, Melbourne, Blackwell Press, 1994, pp 41.1-41.11
3. BORCH-JOHNSEN K, KREINER S: Proteinuria: Value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 294:1651-1654, 1987
4. PYORALA K: Diabetes and heart disease, in Prevention and Treatment of the Diabetic Late Complications, edited by MOGENSEN CE, STANDL E, New York, Walter de Gruyter, 1989, pp 151-168
5. LAHDENPERA S, GROOP PH, TILLY-KIESI M, et al: LDL subclasses in IDDM patients: Relation to diabetic nephropathy. Diabetologia 37:681-688, 1994
6. SIBLEY SD, HOKANSON JE, STEFFES MW, et al: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 22:1165-1170, 1999
7. SAMUELSSON O, ATTMAN PO, KNIGHT-GIBSON C, et al: Complex apolipoprotein B containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 9(8):1482-1488, 1998
8. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P: Progression of renal failure: Role of apolipoprotein B-containing lipoproteins. Kidney Int (Supp 63):S98-101, 1997
9. TASKINEN MR: Hyperlipidaemia in diabetes, in Lipid and Lipoprotein Disorders Bailliere's Clinical Endocrinology and Metabolism, edited by BETTERIDGE DJ, London, Bailliere-Tindall, 1990, pp 743-775
10. FIEVET C, FRUCHART JC: HDL heterogeneity and coronary heart disease. Diabetes Metab Rev 7:155-162, 1991
11. AUSTIN MA, BRESLOW JL, HEMEKENS CH, et al: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
12. THE DCCT RESEARCH GROUP: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. New Engl J Med 329:977-986, 1993
13. THE DCCT RESEARCH GROUP: Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: A multicenter study. Clin Chem 33:2267-2271, 1987
14. EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC): Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111, 1999
15. THE DIABETES CONTROL AND COMPLICATIONS TRIAL/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS RESEARCH GROUP: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
16. EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Grading diabetic retinopathy from stereoscopic color fundus photographs - An extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98(Suppl I):786-806, 1991
17. CLINICAL GUIDE TO LABORATORY TESTS, 3rd edition, edited by TIETZ NW, WB Saunders, Philadelphia,1995, pp 188
18. OTVOS JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48(3-4):171-180, 2002
19. JENKINS AJ, KLEIN RL, CHASSEREAU C, et al: Susceptibility to in vitro oxidation of LDL from patients with well-controlled type 1 diabetes is not increased. Diabetes 45:762-767, 1996
20. JENKINS AJ, LYONS TJ, OTVOS J, et al: NMR analysis of lipoprotein subclasses in the EDIC cohort: Associations with gender and glycemia. Diabetes Care 26:810-818, 2003
21. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
22. COONROD BA, ELLIS D, BECKER DJ, et al: Predictors of microalbuminutia in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16:1376-1383, 1993
23. KLEIN R, KLEIN BE, MOSS SE, et al: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22:743-751, 1999
24. WATTS GF, HARRIS R, SHAW KM: The determinants of early nephropathy in insulin-dependent diabetes mellitus: A prospective study based on the urinary excretion of albumin. Q J Med 79:365-378, 1991
25. RODRIGUEZ JA, CLERIES M, VELA E: Diabetic patients on renal replacement therapy: Analysis of Catalan Registry data. Renal Registry Committee. Nephrol Dial Transplant 12:2501-2509, 1997
26. ARTERIAL HYPERTENSION AND MICROALBUMINURIA IN IDDM: The Italian Microalbuminuria Study. Diabetologia 37:1015-1024, 1994
27. WINOCOUR PH, DURRINGTON PN, BHATNAGAR D, et al: Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. Atherosclerosis 89:49-57, 1991
28. GROOP PH, ELLIOTT T, EKSTRAND A, et al: Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45:974-979, 1996
29. ATTMAN PO, KNIGHT-GIBSON C, TAVELLA M, et al: The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13:2833-2841, 1998
30. MULEC H, JOHNSEN SA, WIKLUND O, BJORCK S: Cholesterol: A renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196-201, 1993
31. HIRANO T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 71:S22-S24, 1999
32. ATTMAN PO, NYBERG G. WILLIAM-OLSSON T, et al: Dyslipoproteinemia in diabetic renal failure. Kidney Int 42:1381-1389, 1992
33. TAMSMA JT, BEVERDAM FH, LEUVEN JA, LEMKES HH: Decreased interstitial apolipoprotein A-I levels in IDDM patients with diabetic nephropathy. Diabetes 44:501-505, 1995
34. PURNELL JQ, MARCOVINA SM, HOKANSON JE, et al: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
35. JENKINS AJ, STEELE J, JANUS E, BEST J: Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 40:787-790, 1991
36. MASER RE, USHER D, BECKER DJ, et al: Lipoprotein(a) concentration shows little relationship to IDDM complications in the Epidemiology of Diabetes Complications Study cohort. Diabetes Care 16:755-758, 1993
37. GROOP PH, VIBERTI GC, ELLIOTT TG, et al: Lipoprotein(a) in type 1 diabetic patients with renal disease. Diabet Med 11:961-967, 1994
38. JERUMS G, ALLEN TJ, TSALAMANDRIS C, et al: Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 36:1037-1044, 1993
39. KRONENBERG F, UTERMANN G, DIEPLINGER H: Lp(a) in renal disease. Am J Kid Dis 27:1-25, 1996
40. KRONENBERG F, KRONENBERG M, KIECHL S, et al: Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck study. Circulation 100:1154-1160, 1999
41. LONGENECKER JC, KLAG MJ, MARCOVINA SM, et al: Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 106:2812-2818, 2002
42. PANZETTA O, COMINACINI L, GARBIN U, et al: Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration. Clin Nephrol 44:303-309, 1995
43. WESTHUYZEN J, SALTISSI D, HEALY H: Oxidation of low density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls. Atherosclerosis 129:199-205, 1997
44. BONNET F, COOPER ME: Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies. Diabetes Metab 26:254-264, 2000
45. ELLIS D, LLOYD C, BECKER DJ, et al: The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis 27:809-818, 1996
46. GARVEY WT, KWON S, ZHENG D, et al: Effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453-462, 2003
47. VERHAGE B, VERVOORT G, WOLKOTTE C, et al: Prevalence of "Syndrome X" features in parents of type 1 diabetic patients with or without nephropathy. Diabetes Care 22:1048-1052, 1999